TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Race Oncology Ltd. ( (AU:RAC) ) has provided an announcement.
Race Oncology Ltd has announced its 2025 Annual General Meeting, scheduled for November 24, 2025, at the State Library NSW in Sydney. The company has provided shareholders with a letter, notice of the meeting, and proxy form, emphasizing the importance of shareholder engagement and participation. This meeting is a key event for stakeholders to discuss the company’s strategic direction and operational updates.
More about Race Oncology Ltd.
Race Oncology Ltd is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, RCDS1, is a small molecule anticancer agent targeting cancer growth regulator MYC. The company is developing a proprietary formulation, RC220, for multiple oncology indications and exploring partnerships to enhance global patient access.
Average Trading Volume: 450,620
Technical Sentiment Signal: Buy
Current Market Cap: A$724M
See more data about RAC stock on TipRanks’ Stock Analysis page.